Solventum (NYSE:SOLV) Stock Rating Lowered by UBS Group

Posted by George Bondi on May 14th, 2026

Solventum (NYSE:SOLV – Get Free Report) was downgraded by equities researchers at UBS Group from a “buy” rating to a “neutral” rating in a research report issued on Thursday, MarketBeat.com reports. They currently have a $50.00 target price on the stock. UBS Group’s price target would suggest a potential downside of 32.82% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. KeyCorp raised their price target on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Mizuho set a $100.00 price target on shares of Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Piper Sandler reduced their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $83.36.

Read Our Latest Analysis on SOLV

Solventum Trading Down 0.9%

NYSE SOLV opened at $74.43 on Thursday. The company has a market cap of $12.89 billion, a price-to-earnings ratio of 9.12, a price-to-earnings-growth ratio of 1.16 and a beta of 0.59. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The business’s fifty day moving average is $67.79 and its 200 day moving average is $74.55.

Solventum (NYSE:SOLV – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the company earned $1.34 earnings per share. The business’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the purchase, the director owned 5,039 shares in the company, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.24% of the company’s stock.

Institutional Trading of Solventum

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hilltop National Bank boosted its holdings in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares in the last quarter. CrossGen Wealth LLC bought a new stake in shares of Solventum during the fourth quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the third quarter worth approximately $25,000. Clearstead Trust LLC raised its position in shares of Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after purchasing an additional 150 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its holdings in shares of Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after purchasing an additional 163 shares in the last quarter.

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.